These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23624842)

  • 1. Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.
    Beeharry N; Rattner JB; Caviston JP; Yen T
    Cell Cycle; 2013 May; 12(10):1588-97. PubMed ID: 23624842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
    Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
    Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic entry upon Topo II catalytic inhibition is controlled by Chk1 and Plk1.
    Arroyo M; Cañuelo A; Calahorra J; Hastert FD; Sánchez A; Clarke DJ; Marchal JA
    FEBS J; 2020 Nov; 287(22):4933-4951. PubMed ID: 32144855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinated requirements of human topo II and cohesin for metaphase centromere alignment under Mad2-dependent spindle checkpoint surveillance.
    Toyoda Y; Yanagida M
    Mol Biol Cell; 2006 May; 17(5):2287-302. PubMed ID: 16510521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
    Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
    Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
    Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
    Parsels LA; Tanska DM; Parsels JD; Zabludoff SD; Cuneo KC; Lawrence TS; Maybaum J; Morgan MA
    Cell Cycle; 2016; 15(5):730-9. PubMed ID: 26890478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic S and G2 checkpoint override causes centromere fragmentation in mitosis.
    Stolz A; Bastians H
    Cell Cycle; 2013 Jun; 12(12):1826-7. PubMed ID: 23759565
    [No Abstract]   [Full Text] [Related]  

  • 11. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.
    Koh SB; Courtin A; Boyce RJ; Boyle RG; Richards FM; Jodrell DI
    Cancer Res; 2015 Sep; 75(17):3583-95. PubMed ID: 26141863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCPH1 Lack of Function Enhances Mitotic Cell Sensitivity Caused by Catalytic Inhibitors of Topo II.
    Arroyo M; Sánchez A; Cañuelo A; Heredia-Molina RF; Martínez-Molina E; Clarke DJ; Marchal JA
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32276518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
    McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
    Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe.
    Chen Y; Chow JP; Poon RY
    Mol Cancer Res; 2012 May; 10(5):626-35. PubMed ID: 22522457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
    Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
    Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
    Jain CK; Roychoudhury S; Majumder HK
    Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01.
    On KF; Chen Y; Ma HT; Chow JP; Poon RY
    Mol Cancer Ther; 2011 May; 10(5):784-94. PubMed ID: 21430130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.